Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.48 |
| ▸ | KDM5A | P29375 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | GABRP | O00591 | 1/20 | 0.41 |
| ▸ | GABRD | O14764 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.41 |
| ▸ | GABRE | P78334 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.41 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.41 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3330730 | 1.00 | POLB (0.64) | POLBEPHX1KDM5ATSHRGABRP | |
| SCHEMBL3761565 | 1.00 | POLB (0.64) | POLBEPHX1KDM5ATSHRGABRP | |
| Hydrochloric Acid SCHEMBL2021306 | 0.98 | POLB (0.62) | POLBEPHX1KDM5ATSHRGABRP | |
| Hydrochloric Acid SCHEMBL2015703 | 0.98 | POLB (0.62) | POLBEPHX1KDM5ATSHRGABRP | |
| Hydrochloric Acid SCHEMBL2015072 | 0.98 | POLB (0.62) | POLBEPHX1KDM5ATSHRGABRP | |
| SCHEMBL2145984 | 0.92 | POLB (0.60) | POLBEPHX1TSHRSLC6A1SLC6A11 | |
| SCHEMBL2145975 | 0.92 | POLB (0.60) | POLBEPHX1TSHRSLC6A1SLC6A11 | |
| Hydrochloric Acid SCHEMBL2146400 | 0.90 | POLB (0.58) | POLBEPHX1KDM5ATSHRSLC6A1 | |
| Hydrochloric Acid SCHEMBL2146019 | 0.90 | POLB (0.58) | POLBEPHX1KDM5ATSHRSLC6A1 | |
| SCHEMBL2146022 | 0.90 | POLB (0.58) | POLBEPHX1TSHRLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113149972-B | 2- (aryl (azacycloalkane-1-yl) methyl) phenol derivatives and use thereof | 四川大学 | 2022-09-13 | — | — | CN | disclosed |
| CN-113149972-A | 2- (aryl (azacycloalkane-1-yl) methyl) phenol derivatives and use thereof | 四川大学 | 2021-07-23 | — | — | CN | disclosed |
| US-8669266-B2 | Quinoline-carboxamide derivatives as P2Y12 antagonists | SANOFI (FR) | 2014-03-11 | — | — | US | disclosed |
| US-20110160180-A1 | Cannabinoid Receptor Ligands | ASTRAZENECA AB (SE) | 2011-06-30 | — | — | US | disclosed |
| US-20110160180-A1 | Cannabinoid Receptor Ligands | ASTRAZENECA AB (SE) | 2011-06-30 | — | — | US | disclosed |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2148871-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | disclosed |
| US-20090062251-A1 | Novel Compounds 002 | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062251-A1 | Novel Compounds 002 | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| WO-2008128647-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062251-A1 | Novel Compounds 002 | OPRL1, OPRK1, OPRM1 | POLB 4496/4885EPHX1 1364/4885KDM5A 3738/4885 |
| US-20110160180-A1 | Cannabinoid Receptor Ligands | CNR1, CNR2, OPRL1 | POLB 4715/4885EPHX1 1309/4885KDM5A 3142/4885 |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | P2RY12, P2RY1, P2RY2 | POLB 1874/4885EPHX1 428/4885KDM5A 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.